Non-dilutive funding
The financing does not dilute the founders’ ownership stake, keeping motivation high, while complementing the equity capital.
Bespoke financing
Loans can be secured or unsecured and provide different levels of subordination (including contingent/participating loans).
Hands-off approach
The EIB assumes no direct involvement in daily management.
Signalling effect
The EIB’s financing is often seen as a quality stamp, helping the project attract additional investors.
Who is eligible
- SMEs and mid-caps
What is eligible
Investments in research & development (purchase or renovation of assets, increasing working capital, etc) which are undertaken over a period of up to 3 years. Minimum commitment of €7.5 million, covering a maximum of 50% of the total investment costs. Companies must be able to demonstrate sound corporate governance, viable business plans, and sustainable capital structures. The investments must target EIB priorities (especially Innovation and Skills).
Find information on pricing, geographical availability and other terms.
Financing options
Loans
Lending to clients of all sizes to support sustainable growth and job creation
Equity
Through our investments in equity and funds we stimulate and catalyse private capital
Guarantees
Covering risks of large and small projects, as well as loan portfolios
Advisory services
Technical and financial expertise for our clients
Press releases
- Lithuania: Long-term support for Brolis EIB venture debt from European Guarantee Fund
- Belgium: Belgian industrial biotech innovator Inbiose secures €15 million from EIB
- Belgium: EIB boosts innovative biotech company Univercells with €30 million of European financing to support COVID-19-related projects
- Belgium: Bone Therapeutics secures up to €16 million financing from EIB
- Austria: EIB provides €7.5 million to artificial intelligence software innovator Cortical.io
- France: EIB provides €50 million to support Forsee Power's growth
- France: OSE Immunotherapeutics enters a loan agreement of up to €25 million with the EIB
- France: EIB supports AB Science in its COVID-19 development programme
- Denmark: EU boosts Evaxion’s artificial intelligence vaccine research
- Germany: EIB provides KINEXON with €15 million to develop their internet of things technology
- Italy: EU backs MMI’s Robotic System for Microsurgery
- Sweden: EU backs cancer treatment research with quasi equity investment
- Spain: Biotech innovation - the EIB provides €20 million in financing to Sanifit to develop treatments for vascular calcification
- Poland: EIB lends up to €10 million to Scope Fluidics to develop diagnostics equipment for infectious diseases
- Italy: EU support for biotech’s red blood cell technology to treat rare diseases
- EIB signs collaboration with Israel Innovation Authority and €50 million financing agreement with Pluristem to develop therapies for COVID-19 and other unmet medical needs
- Netherlands: Europe supports AM-Pharma through EUR 24m InnovFin facility
- Slovenia: Investment Plan for Europe - EIB signs €12 million loan with energy services provider Resalta
- Germany: EIB provides funding of €40 million to ITM
- Poland: #InvestEU – EIB finances digital money transfer service Azimo to make international payments affordable to all
- France : Plan d’investissement - la BEI finance le développement de Famoco
- France: Median Technologies announces the signing of EUR 35 million finance contract with the EIB
- Germany: EIB provides funding of EUR 50 million to BioNTech as part of the Investment Plan for Europe
- Estonia: #InvestEU - EUR 50m quasi-equity facility for ride-hailing platform Bolt
- Germany: EU Investment Plan - EIB lends Fazua EUR 12 million